CAMBRIDGE - The Japan Agency for Medical Research and Development (AMED) announced that Saisei Ventures LLC was selected as one of nine registered venture capital firms in AMED's Strengthening Program for Pharmaceutical Startup Ecosystem initiative.

Through this initiative, AMED subsidizes the development of therapeutic assets by providing additional grant funding to ventures that have received investments from certified VC firms.

Under the Strengthening Program for Pharmaceutical Startup Ecosystem initiative, AMED certifies VC firms and fund managers that have a demonstrated track record of therapeutic investment and can provide specialized hands-on commercialization support for preclinical to clinical stage drug development. A total of JPY 350 billion (USD 2.6 billion) has been allocated to this initiative by the Ministry of Economy, Trade and Industry (METI). Companies that are successfully selected for funding by AMED will receive a minimum of JPY 3 billion, with certified VC firms providing investment capital of JPY 1+ billion and AMED providing a two times matching grant of JPY 2+ billion per company's therapeutic program.

Contact:

Email: info@saiseiventures.com

(C) 2023 Electronic News Publishing, source ENP Newswire